Analysis of clinical adverse reactions of apatinib for the treatment of malignant tu-mors
10.3969/j.issn.1000-8179.2018.04.269
- VernacularTitle:甲磺酸阿帕替尼治疗恶性肿瘤的临床不良反应分析
- Author:
Jiaqi SHI
1
;
Chao LIU
;
Yanqiao ZHANG
;
Chunhui ZHANG
Author Information
1. 哈尔滨医科大学附属肿瘤医院内八科 哈尔滨市150081
- Keywords:
apatinib;
malignant tumor;
antiangiogenic targeted therapy;
adverse reactions;
targeting drugs
- From:
Chinese Journal of Clinical Oncology
2018;45(4):191-195
- CountryChina
- Language:Chinese
-
Abstract:
Antiangiogenic targeted therapy plays an important role in the treatment of malignant tumors,especially in the process of antitumor treatment including transformation stage,late stage,and maintenance stage.Apatinib(YN968D1)is a self-developed antian-giogenic targeted agent that was approved and launched for third-line and subsequent-line treatment for advanced gastric adenocarci-noma or gastro-esophageal junction adenocarcinoma.Moreover,the use of apatinib for other multiple solid tumors has been investi-gated.With an increase in the number of clinical studies on apatinib,concerns have been raised about its safety.Hence,we highlight the common adverse reactions of apatinib in clinical application and the incidences of various adverse events in different tumor treat-ments.We provide a comprehensive analysis of available clinical data and compare the advantages and disadvantages of apatinib with other common antiangiogenic drugs regarding their adverse reactions.Overall,these results will help to provide a better understand-ing of the safety of this medicine in the hope of helping physicians to provide patients with a safe and effective treatment.
